Pentam
(Pentamidine isethionate)ApprovedSmall molecule
Pentamidine isethionate is used to treat and prevent a serious lung infection called PCP (pneumocystis pneumonia) that commonly affects people with weakened immune systems, particularly those with HIV/AIDS. It can be given as an injection or inhaled as a mist into the lungs.[2] Pentam is currently approved and in use across 7 indications[4].[1]
Pentam is one of 132 small molecule programs targeting HIV infection. It is currently in Approved.
7
Indications
23
Total Trials
1
Active Trials
131
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Pentam
FFresenius Kabi Oncology Ltd.
Approved
Jakafi
IncytePreclinical
Primaquine
SanofiPreclinical
Acanya
PfizerPreclinical
Prevacid
TakedaPreclinical
Innohep
Alnylam PharmaceuticalsPreclinical
Avlosulfon
AAlmirall, S.A.
Preclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Advil
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pneumonia19 trials
Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000707·20 enrolled
Show 16 more trials
A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis Carinii Pneumonia
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000974·16 enrolled
Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000730·240 enrolled
A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000727·322 enrolled
Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000722·45 enrolled
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001003·20 enrolled
Cutaneous Leishmaniasis2 trials
Prevention1 trial
A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000991·600 enrolled
Regulatory
FDA Approval Timeline[5]
Oct 16, 1984
PENTAM
NDA NDA019264
Jun 15, 1989
NEBUPENT
NDA NDA019887
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Pentam drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Pentamidine isethionate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- FFresenius Kabi Oncology Ltd.